IBBJ

Junior Biotechnology ETF

IBBJ // Junior Biotechnology ETF

Why Invest in Junior Biotech?

  • Junior biotech companies, with a market capitalization that is less then $5 billion, have the potential advantage of a Food and Drug Administration more receptive to new cutting-edge and rare-disease therapies. They are possibly also strengthened by increased patient lobbying and greater willingness by insurers to pay for treatments. Combined with the potential for mergers-and-acquisitions and the U.S. government’s recent gigantic Covid-19 aid to small and mid-sized companies, small-caps seemed likely to lead the domestic recovery.
  • The value of the global pharmaceutical market rose from about US$390 billion in 2001, to about US$1.25 trillion at the end of 2019.1
  • Whether for cancer research, or a vaccine or treatment for Covid-19, we believe the strong demand side continues to combine with government regulation and policies prioritizing these sectors.
  • In uncertain and unpredictable times, biotechnology benchmarks have been known to beat the wider market.2

Why the Defiance Junior Biotech ETF?

  • IBBJ offers the investor liquid, transparent and low-cost* access to junior companies that are classified as either biotechnology or pharmaceutical. The ETF can be traded intraday, providing flexible yet targeted exposure to a potentially growing sector.
  • The underlying Nasdaq Junior Biotechnology Index tracks approximately 176 companies from over 16 countries.

Index Description

  • The Nasdaq Junior Biotechnology Index is a modified market capitalization weighted index that tracks the performance of small-cap “junior” companies listed on the Nasdaq Stock Market® (Nasdaq®), which are under $5 billion of market capitalization. They must be classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark (ICB).
  • These are companies engaged in biotech research and development, the sale or licensing of biological substances for the purposes of drug discovery and diagnostic development; and pharmaceutical manufacturers of prescription or over-the counter drugs, including vaccines and development and manufacturing companies.

1 “Revenue of the worldwide pharmaceutical market from 2001 to 2019,” Statista, https://www.statista.com/statistics/263102/pharmaceutical-market-worldwide-revenue-since-2001/

2 “Biotech ETFs in the Spotlight, Why They’ll Remain There,” Tom Lydon, ETF Trends, June 18, 2020, https://www.etftrends.com/etf-building-blocks-channel/biotech-etfs-in-the-spotlight-why-they-can-remain-there/

3 Diversification does not assure a profit, nor does it protect against a loss in a declining market.

* Commissions may be charged on trades.

FUND DATA & PRICING
Net Assets as of 11/25/2020 $6.07m
NAV $30.34
Shares Outstanding 200,000
Premium/discount Percentage 0.01%
Closing Price $30.34
Median 30 Day Spread Percentage 0.17

Data as of 11/25/2020

IOPV, or indicative Optimized Portfolio Value, is a calculation disseminated by the stock exchange that approximates the Fund's NAV every fifteen seconds throughout the trading day.

RETURNS
{{v}}{{($index != 0 && $parent.$index != 0) ? '%':''}}
No Data Found
RETURNS
{{v}}{{($index != 0 && $parent.$index != 0) ? '%':''}}
No Data Found
RETURNS
{{v}}{{($index != 0 && $parent.$index != 0) ? '%':''}}
No Data Found

The performance data quoted represents past performance. Past performance does not guarantee future results. The investment return and principal value of an investment will fluctuate so that an investor's shares, when sold or redeemed, may be worth more or less than their original cost and current performance may be lower or higher than the performance quoted. Performance current to the most recent month-end can be obtained by calling 833.333.9383.

Short term performance, in particular, is not a good indication of the fund's future performance, and an investment should not be made based solely on returns.

Market price is the price at which shares in the ETF can be brought or sold on the exchanges during trading hours, while the net asset value (NAV) represents the value of each share's portion of the fund's underlying assets and cash at the end of the trading day.

HOLDINGS SNAPSHOT
Percentage Of Net Assets Name Identifier Shares Held Market Value
3.56% MIRATI THERAPEUTICS INC MRTX 956 222,308.24
2.64% CRISPR THERAPEUTICS AG CRSP 1,356 164,821.80
2.33% ARGENX SE ARGX 516 145,300.44
2.27% ULTRAGENYX PHARMACEUTICAL INC COM RARE 1,156 141,517.52
2.24% DENALI THERAPEUTICS INC DNLI 2,276 139,450.52
2.15% ACCELERON PHARMA INC XLRN 1,140 134,235.00
1.97% ARROWHEAD PHARMACEUTICALS INC COM ARWR 1,952 122,956.48
1.94% ADAPTIVE BIOTECHNOLOGIES CORP COM ADPT 2,576 121,072.00
1.85% EXELIXIS INC EXEL 5,932 115,140.12
1.84% AMICUS THERAPEUTICS INC FOLD 4,944 114,898.56
Data as of 11/30/2020. Fund holdings are subject to change at any time and should not be considered recommendations to buy or sell any security.